Figure 2.
Systemic autophagy deficiency does not impact on the efficacy of anthracycline-based immunogenic chemotherapy. (A-C) Wild type (WT) autophagy competent C57BL/6 mice (A) or autophagy deficient Atg4b−/- (B) and Becn1+/- (C) mice were inoculated subcutaneously (s.c.) with murine fibrosarcoma MCA205 cells. When tumors reached a size of 25 mm2, mice received a single injection (i.p) of mitoxantrone (MTX) or an equivalent volume of PBS and tumor growth was routinely assessed. From left to right: average (± S.E.M) tumor growth curves of treated with PBS or MTX-based chemotherapy; tumor size distribution at day 26 of data; individual growth curves from mice treated with MTX or PBS. Data represent a pool of three different experiments. Statistical analysis of tumor growth curves was performed by Wald test whereas tumor size distribution at defined time points was analyzed by means of an unpaired t test. ** p < 0.01; *** p < 0.001.